Your browser doesn't support javascript.
loading
Towards the development of a SARS-CoV-2 variant risk assessment tool: expert consultation on the assessment of scientific evidence on emerging variants.
Worp, Nathalie; Subissi, Lorenzo; Perkins, Mark D; Van Kerkhove, Maria D; Agrawal, Anurag; Chand, Meera; van Beek, Janko; Oude Munnink, Bas B; Koopmans, Marion P G.
Affiliation
  • Worp N; Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Subissi L; World Health Organization, Geneva, Switzerland.
  • Perkins MD; World Health Organization, Geneva, Switzerland.
  • Van Kerkhove MD; World Health Organization, Geneva, Switzerland.
  • Agrawal A; Trivedi School of Biosciences, Ashoka University, Sonipat, India.
  • Chand M; UK Health Security Agency, London, UK.
  • van Beek J; Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Oude Munnink BB; Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Koopmans MPG; Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands. Electronic address: m.koopmans@erasmusmc.nl.
Lancet Microbe ; 4(10): e830-e836, 2023 10.
Article in En | MEDLINE | ID: mdl-37640039
ABSTRACT
A systematic approach is required for the development of an evidence-based risk assessment tool to robustly estimate the risks and implications of SARS-CoV-2 variants. We conducted a survey among experts involved in technical advisory roles for WHO to capture their assessment of the robustness of different study types that provide evidence for potential changes in transmissibility, antigenicity, virulence, treatability, and detectability of SARS-CoV-2 variants. The views of 62 experts indicated that studies could be grouped on the basis of robustness and reliability for the different risk indicators mentioned. Several study types that experts scored as providing reliable evidence and that can be performed in a timely manner were identified. Although experts from different technical areas had varying responses, there was agreement on the highest and lowest scoring study types. These findings can help to prioritise, harmonise, and optimise study designs for the further development of a systematic, evidence-based, SARS-CoV-2 variant risk assessment tool.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Lancet Microbe Year: 2023 Type: Article Affiliation country: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Lancet Microbe Year: 2023 Type: Article Affiliation country: Netherlands